A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
about
Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogensDevelopment of Novel Adenoviral Vectors to Overcome Challenges Observed With HAdV-5-based ConstructsAssociation of ESAT-6/CFP-10-induced IFN-γ, TNF-α and IL-10 with clinical tuberculosis: evidence from cohorts of pulmonary tuberculosis patients, household contacts and community controls in an endemic setting.An Adenoviral Vector Based Vaccine for Rhodococcus equiCurrent status of new tuberculosis vaccine in children.Increased TNF-α/IFN-γ/IL-2 and Decreased TNF-α/IFN-γ Production by Central Memory T Cells Are Associated with Protective Responses against Bovine Tuberculosis Following BCG Vaccination.Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine.Emerging drugs and alternative possibilities in the treatment of tuberculosis.Towards new TB vaccines: What are the challenges?Novel viral vectors in infectious diseases.Rationalized design of a mucosal vaccine protects against Mycobacterium tuberculosis challenge in mice.Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized Trial.Polyfunctional CD4+ T Cells As Targets for Tuberculosis VaccinationThe current status, challenges, and future developments of new tuberculosis vaccines.Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate TB Subunit Vaccine.
P2860
Q26750912-5B16AFFD-977F-44D3-AA07-FFC56088084AQ26782083-C747913D-8DEC-4381-AFC5-FA3ED47D0836Q33900138-FE38DBD3-5189-49D9-9EB3-44106A105E3AQ35967948-69980113-EEDD-43AE-B176-90A886B552B8Q37130796-0518DC94-AC95-4E43-B18A-AB55A739E54BQ37342751-66800093-3E96-4969-9235-61346B7B6C67Q37479096-E111DAFA-5DC0-431B-B06B-0B0085472481Q38724073-F7350235-7409-404E-A025-20F7A9FCC818Q38767468-22B699F9-A9A3-4503-A7CF-767E3FA84377Q40059020-4C61157B-C076-46B5-98AF-D244C689DF81Q40309267-197308A4-9381-4441-93E9-9146A8FB31BCQ40382721-08F23FED-A8D7-48B4-8254-E8F9064FE7C3Q42373425-8ABEE75C-B3A7-4417-A858-FD13B34689B5Q52337140-54F5D05A-AB5E-46CA-AC85-96EF619AF767Q54234703-34F42DEE-707F-4941-8A58-7242D178EBC9
P2860
A double-blind, randomised, placebo-controlled, dose-finding trial of the novel tuberculosis vaccine AERAS-402, an adenovirus-vectored fusion protein, in healthy, BCG-vaccinated infants.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A double-blind, randomised, pl ...... althy, BCG-vaccinated infants.
@en
A double-blind, randomised, pl ...... althy, BCG-vaccinated infants.
@nl
type
label
A double-blind, randomised, pl ...... althy, BCG-vaccinated infants.
@en
A double-blind, randomised, pl ...... althy, BCG-vaccinated infants.
@nl
prefLabel
A double-blind, randomised, pl ...... althy, BCG-vaccinated infants.
@en
A double-blind, randomised, pl ...... althy, BCG-vaccinated infants.
@nl
P2093
P921
P1433
P1476
A double-blind, randomised, pl ...... ealthy, BCG-vaccinated infants
@en
P2093
B Shepherd
E M Lazarus
H Geldenhuys
P304
P356
10.1016/J.VACCINE.2015.03.070
P407
P577
2015-04-28T00:00:00Z